立体定向消融体部放疗治疗寡转移性前列腺癌的前瞻性临床试验
这项前瞻性临床试验评估了单次20 Gy立体定向消融体部放疗(SABR)治疗寡转移性前列腺癌的安全性与可行性。33例患者共50处寡转移灶接受治疗,1年和2年局部无进展生存率分别为97%和93%,远处无进展生存率分别为58%和39%。单次SABR可行且并发症少,未接受雄激素剥夺治疗(ADT)的患者中2年免于ADT比例为48%,生活质量维持稳定。
要点
- 单次20 Gy SABR治疗寡转移性前列腺癌可行,97%病例按计划完成。
- 1年和2年局部无进展生存率分别为97%和93%,远处无进展生存率分别为58%和39%。
- 未接受ADT者2年免于ADT比例为48%,生活质量无显著下降。
核心结论
- 单次SABR治疗寡转移性前列腺癌可行且并发症少,超过三分之一患者在2年时无进展且免于ADT,生活质量维持稳定。
研究设计与样本
- 前瞻性临床试验,2013至2014年连续纳入33例经CT、骨扫描和氟化钠PET筛查的寡转移性前列腺癌患者,共50处寡转移灶,随访2年。
主要发现
- 中位年龄70岁,Gleason评分≥8者15例(45%),单纯骨转移20例、单纯淋巴结转移12例、混合转移1例。
- SABR按计划完成率97%,仅1例(3.0%)发生3级不良事件(椎体骨折),无患者死亡。
- 1年和2年局部无进展生存率分别为97%(95%CI:91-100)和93%(95%CI:84-100)。
- 1年和2年远处无进展生存率分别为58%(95%CI:43-77)和39%(95%CI:25-60)。
- 未接受ADT者(n=22)2年免于ADT比例为48%,生活质量较基线无显著差异。
关键数值与推荐
- 每处寡转移灶接受单次20 Gy SABR。
- 毒性分级采用不良事件通用术语标准4.0版,生活质量采用EORTC QLQ-C30和QLQ-BM22评估。
临床怎么用
- 对于寡转移性前列腺癌患者,单次20 Gy SABR可作为可行的局部消融策略,有助于延迟ADT启动并维持生活质量。
局限性
- 样本量小,随访时间有限,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for oligometastatic prostate cancer. However, limited prospective evidence is available. OBJECTIVE: To determine the safety and feasibility of single fraction SABR for patients with oligometastatic prostate cancer. Secondary endpoints were local and distant progression-free survival (LPFS and DPFS), toxicity, quality of life (QoL), and prostate-specific antigen response. DESIGN, SETTING, AND PARTICIPANTS: In a prospective clinical trial, patients were screened with computed tomography, bone scan, and sodium fluoride positron emission tomography scan and had one to three oligometastases. Kaplan-Meier methods were used to determine LPFS and DPFS. Toxicity was graded using Common Terminology Criteria for Adverse Event version 4.0. QoL was assessed using European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-BM22 at 1, 3,12, and 24 mo. INTERVENTION: A single fraction of 20-Gy SABR to each lesion. RESULTS AND LIMITATIONS: Between 2013 and 2014, 33 consecutive patients received SABR to a total of 50 oligometastases and were followed for 2 yr. The median age was 70 yr. The Gleason score was ≥8 in 15 patients (45%). Twenty patients had bone only, 12 had node only, and one had mixed disease. SABR was feasible and delivered as planned in 97% of cases. There was one grade 3 adverse event (3.0%, vertebral fracture). No patient died. The 1 and 2-yr LPFS was 97% (95% confidence interval [CI]: 91-100) and 93% (95% CI: 84-100), and DPFS was 58% (95% CI: 43-77) and 39% (95% CI: 25-60), respectively. In those not on androgen deprivation therapy (ADT; n=22), the 2-yr freedom from ADT was 48%. There was no significant difference from baseline QoL observed. Limitations include small sample size, limited duration of follow-up, and lack of a control arm. CONCLUSIONS: A single SABR session was feasible and associated with low morbidity in this cohort. Over one-third of patients did not progress and were free from ADT at 2-yr. QoL measures were maintained with this treatment strategy. PATIENT SUMMARY: This clinical trial investigated single treatment stereotactic radiotherapy for low volume advanced prostate cancer. The approach was found to be safe with avoidance of hormone therapy in almost half of the participants at 2 yr.
引用
- Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018. PMID: 30227924. doi:10.1016/j.eururo.2018.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。